A new use of hydroxyurea for preventing, alleviating, or treating systemic inflammatory response syndrome or sepsis is disclosed. Hydroxyurea can control the activity of neutrophils that are immune cells involved in inflammatory mechanisms, and thus can protect an individual from side effects or conditions caused by systemic inflammatory responses which can occur due to exposure to microorganisms such as bacteria or viruses. Thus, a pharmaceutical composition containing hydroxyurea as an active ingredient can prevent, alleviate, or treat systemic inflammatory response syndrome or sepsis in an individual and ultimately can remarkably increase the survival rate of the individual. The composition may be effective in preventing, alleviating, or treating neutrophilia which can occur when exposed to microorganisms such as bacteria or viruses, wherein the viruses include viruses for therapeutic purposes, such as oncolytic viruses as well as pathogenic viruses such as influenza virus or coronavirus.

A new use of hydroxyurea for preventing, alleviating, or treating systemic inflammatory response syndrome or sepsis is disclosed. Hydroxyurea can control the activity of neutrophils that are immune cells involved in inflammatory mechanisms, and thus can protect an individual from side effects or conditions caused by systemic inflammatory responses which can occur due to exposure to microorganisms such as bacteria or viruses. Thus, a pharmaceutical composition containing hydroxyurea as an active ingredient can prevent, alleviate, or treat systemic inflammatory response syndrome or sepsis in an individual and ultimately can remarkably increase the survival rate of the individual. The composition may be effective in preventing, alleviating, or treating neutrophilia which can occur when exposed to microorganisms such as bacteria or viruses, wherein the viruses include viruses for therapeutic purposes, such as oncolytic viruses as well as pathogenic viruses such as influenza virus or coronavirus.

Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

Described herein, inter alia, are compositions and methods for modulating mu opioid receptor activity.

Methods, compounds, compositions, and kits for the treatment of cancer, comprising TLR2 agonists, particularly di-palmitoyl-S-glyceryl-cysteine (Pam2Cys) derivatives and conjugates, are provided. In one aspect, methods of treating, preventing or minimizing the progression of cancer comprising the administration of a compound comprising a Pam2Cys moiety and a polyethylene glycol (PEG) are provided.

Methods, compounds, compositions, and kits for the treatment of cancer, comprising TLR2 agonists, particularly di-palmitoyl-S-glyceryl-cysteine (Pam2Cys) derivatives and conjugates, are provided. In one aspect, methods of treating, preventing or minimizing the progression of cancer comprising the administration of a compound comprising a Pam2Cys moiety and a polyethylene glycol (PEG) are provided.

This disclosure relates to methods and compositions for treating sickle cell anemia or thalassemia in a subject in need thereof. As described herein in a first aspect the present disclosure provides a method of treating an inherited blood disorder in a subject In need thereof comprising administering to the subject a therapeutically effective amount of a bromodomain and extra-terminal motif (BET) protein inhibitor.

This disclosure relates to methods and compositions for treating sickle cell anemia or thalassemia in a subject in need thereof. As described herein in a first aspect the present disclosure provides a method of treating an inherited blood disorder in a subject In need thereof comprising administering to the subject a therapeutically effective amount of a bromodomain and extra-terminal motif (BET) protein inhibitor.

This invention relates to inhibitors of UDP-glucose dehydrogenase, and more particularly to UDP-glucose dehydrogenase inhibitors that are useful in the treatment of prostate cancer. Methods of inhibiting UDP-glucose dehydrogenase and improving the efficacy of additional prostate cancer therapies are also provided.

This invention relates to inhibitors of UDP-glucose dehydrogenase, and more particularly to UDP-glucose dehydrogenase inhibitors that are useful in the treatment of prostate cancer. Methods of inhibiting UDP-glucose dehydrogenase and improving the efficacy of additional prostate cancer therapies are also provided.